The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes. The study will last about 20 weeks for each participant, not including screening.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
24
Profil Institut für Stoffwechselforschung
Neuss, North Rhine-Westphalia, Germany
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through 24 weeks
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3305677
PK: Cmax of LY3305677
Time frame: Baseline through 48 hours postdose
PK: Area Under the Concentration-Time Curve (AUC) of LY3305677
PK: AUC of LY3305677
Time frame: Baseline through 48 hours postdose
Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose
PD: Change from Baseline in Fasting Plasma Glucose
Time frame: Baseline, through Week 16
PD: Change from Baseline in Fasting Plasma Insulin
PD: Change from Baseline in Fasting Plasma Insulin
Time frame: Baseline, through Week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.